172 related articles for article (PubMed ID: 10022736)
1. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR).
Ben-Josef E; Yang SY; Ji TH; Bidart JM; Garde SV; Chopra DP; Porter AT; Tang DG
J Urol; 1999 Mar; 161(3):970-6. PubMed ID: 10022736
[TBL] [Abstract][Full Text] [Related]
2. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer.
Mariani S; Salvatori L; Basciani S; Arizzi M; Franco G; Petrangeli E; Spera G; Gnessi L
J Urol; 2006 Jun; 175(6):2072-7; discussion 2077. PubMed ID: 16697805
[TBL] [Abstract][Full Text] [Related]
3. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone.
Zheng W; Lu JJ; Luo F; Zheng Y; Feng Yj; Felix JC; Lauchlan SC; Pike MC
Gynecol Oncol; 2000 Jan; 76(1):80-8. PubMed ID: 10620446
[TBL] [Abstract][Full Text] [Related]
4. The role of serotonin (5-hydroxytryptamine1A and 1B) receptors in prostate cancer cell proliferation.
Siddiqui EJ; Shabbir M; Mikhailidis DP; Thompson CS; Mumtaz FH
J Urol; 2006 Oct; 176(4 Pt 1):1648-53. PubMed ID: 16952708
[TBL] [Abstract][Full Text] [Related]
5. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
[TBL] [Abstract][Full Text] [Related]
6. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
[TBL] [Abstract][Full Text] [Related]
7. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein expression independently predicts clinical outcome in prostate cancer.
Cornford PA; Dodson AR; Parsons KF; Desmond AD; Woolfenden A; Fordham M; Neoptolemos JP; Ke Y; Foster CS
Cancer Res; 2000 Dec; 60(24):7099-105. PubMed ID: 11156417
[TBL] [Abstract][Full Text] [Related]
9. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer.
van der Poel HG
Eur Urol; 2005 Dec; 48(6):1051-8. PubMed ID: 16257107
[TBL] [Abstract][Full Text] [Related]
11. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.
Seth D; Shaw K; Jazayeri J; Leedman PJ
Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mutant D567G but not wild-type human FSH receptor overexpression provides FSH-independent and promiscuous glycoprotein hormone Sertoli cell signaling.
Allan CM; Lim P; Robson M; Spaliviero J; Handelsman DJ
Am J Physiol Endocrinol Metab; 2009 May; 296(5):E1022-8. PubMed ID: 19293333
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
14. [Preliminary study on pathway of follicle-stimulating hormone on human epithelial ovarian cancer cell proliferation].
Sheng L; Liu DY; Shen K
Zhonghua Fu Chan Ke Za Zhi; 2003 Dec; 38(12):752-5. PubMed ID: 14728848
[TBL] [Abstract][Full Text] [Related]
15. Regulation of growth hormone receptors in human prostate cancer cell lines.
Bidosee M; Karry R; Weiss-Messer E; Barkey RJ
Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305
[TBL] [Abstract][Full Text] [Related]
16. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
[TBL] [Abstract][Full Text] [Related]
17. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
18. Expression of basal cell keratins in human prostate cancer metastases and cell lines.
van Leenders GJ; Aalders TW; Hulsbergen-van de Kaa CA; Ruiter DJ; Schalken JA
J Pathol; 2001 Dec; 195(5):563-70. PubMed ID: 11745692
[TBL] [Abstract][Full Text] [Related]
19. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
20. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
